Clinical Trial Update: Topical KB105 Gene Therapy for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for topical KB105 gene therapy targeting TGM1-related autosomal recessive congenital ichthyosis, with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tgm-1 Related Autosomal Recessive Congenital Ichthyosis

Drugs mentioned

• KB105

Snippet

Sponsor: Krystal Biotech, Inc. | Conditions: TGM-1 Related Autosomal Recessive Congenital Ichthyosis | Phase 1, Phase 2 | Status: UNKNOWN